DOJOLVITM is Canada’s first and only prescription drug to treat long-chain fatty acid oxidation disorders (LC-FAOD) in children and adults.
LC-FAODs are a group of rare, genetic, life-threatening disorders caused by defects in the enzymes needed to produce energy from fatty acids. DOJOLVI is a highly purified, synthetic, 7-carbon fatty acid triglyceride specifically designed to provide medium-chain, odd-carbon fatty acids as an energy source and metabolite replacement for people with LC-FAOD.
Patients who meet their provinces’ coverage criteria can now have their DOJOLVI funded. The links below outline each province’s reimbursement criteria. In Quebec, DOJOLVI is approved but not yet contracted.
Ultragenyx, the manufacturer of DOJOLVI, offers a support program called UltraCare®. This program helps patients and caregivers understand insurance coverage and may also assist patients in finding support for access to Dojolvi. Dedicated UltraCare Nurse Case Managers are available Monday through Friday from 8 a.m. to 8 p.m. Eastern Time at 1 -833-388-5872 (U-LTRA) to answer any questions you may have.